Atopic Dermatitis | Access & Reimbursement | US | 2023
The treatment landscape for atopic dermatitis (AD) in the United States is undergoing a revolution. Since 2017, six agents have been approved by the FDA (four of these since the start of 2021), including two systemic JAK inhibitors, two nonsteroidal topical therapies, and two injectable biologic drugs. Newer topical agents like Pfizer’s PDE-4 inhibitor Eucrisa (crisaborole) and Incyte’s topical JAK inhibitor Opzelura (ruxolitinib) are expanding treatment options for mild to moderate AD, while newer options for the treatment of moderate to severe AD include injectable targeted biologics (Sanofi / Regeneron’s Dupixent [dupilumab] and LEO Pharma’s Adbry [tralokinumab]) and systemic JAK inhibitors (Pfizer’s Cibinqo [abrocitinib] and AbbVie’s Rinvoq [upadacitinib]). While Dupixent and Eucrisa, both approved in 2017, have established their niches in AD treatment, payer policies affecting more recently approved therapies will influence physician prescribing of and patient access to these newer therapies. This report will explore in depth the potential of these newer therapies to reshape the AD treatment landscape and drug market.
QUESTIONS ANSWERED
- What are the current prescribing practices for AD, and how are they impacted by payer policy?
- What are physicians’ and payers’ opinions of Opzelura, Adbry, Cibinqo, and Rinvoq, and how has their availability for AD impacted physician prescribing and payer reimbursement?
- How will dermatologists’ prescribing of established agents by line of therapy shift as these new agents are incorporated into the treatment algorithm?
- As systemic JAK inhibitors are granted label expansions for AD, what do payers say about the use of indication-based formularies?
- What are payers’ and physicians’ perspectives on promising emerging agents such as Dermira’s lebrikizumab, Chugai / Dermira / Mahuro’s nemolizumab, and Arcutis’s ARQ-151?
CONTENT HIGHLIGHTS
Geography: United States
Primary Research: Survey of 100 U.S. dermatologists. Survey of 30 U.S. managed care organization (MCO) pharmacy and medical directors (PDs/MDs).
Key Drugs Covered: Adbry, Cibinqo, Dupixent, Eucrisa, Olumiant, Opzelura, Rinvoq, ARQ-151, lebrikizumab, nemolizumab.
PRODUCT DESCRIPTION
U.S. Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment. Each report includes up-to-date analyses of drug coverage and restriction policies as well as payer and prescriber perspectives on key marketed drugs and their receptivity to emerging therapies.
